DaVita HealthCare Partners’ (DVA) “Hold” Rating Reaffirmed at KeyCorp
A number of other research firms also recently weighed in on DVA. Robert W. Baird reaffirmed a hold rating and issued a $63.00 target price on shares of DaVita HealthCare Partners in a research report on Friday. Royal Bank Of Canada decreased their target price on shares of DaVita HealthCare Partners from $64.00 to $60.00 and set a sector perform rating for the company in a research report on Wednesday, November 8th. Bank of America Corporation decreased their target price on shares of DaVita HealthCare Partners from $75.00 to $66.00 and set a neutral rating for the company in a research report on Wednesday, November 8th. TheStreet downgraded shares of DaVita HealthCare Partners from a b rating to a c+ rating in a research report on Wednesday, August 2nd. Finally, Jefferies Group LLC reaffirmed a hold rating and issued a $70.00 target price on shares of DaVita HealthCare Partners in a research report on Thursday, August 3rd. Four investment analysts have rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the stock. The company has an average rating of Hold and a consensus price target of $63.00.
DaVita HealthCare Partners (DVA) traded down $0.01 on Monday, reaching $54.99. 1,329,500 shares of the company’s stock traded hands, compared to its average volume of 1,587,000. The company has a current ratio of 1.40, a quick ratio of 1.35 and a debt-to-equity ratio of 1.79. The firm has a market capitalization of $10,407.74, a price-to-earnings ratio of 15.71, a PEG ratio of 11.05 and a beta of 0.98. DaVita HealthCare Partners has a 12 month low of $52.51 and a 12 month high of $70.16.
DaVita HealthCare Partners (NYSE:DVA) last issued its quarterly earnings data on Tuesday, November 7th. The company reported $0.81 EPS for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.13). DaVita HealthCare Partners had a return on equity of 13.31% and a net margin of 3.40%. The company had revenue of $3.92 billion for the quarter, compared to analyst estimates of $3.91 billion. During the same quarter in the previous year, the business earned $0.95 earnings per share. The company’s revenue was up 5.2% on a year-over-year basis. research analysts forecast that DaVita HealthCare Partners will post 3.43 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “DaVita HealthCare Partners’ (DVA) “Hold” Rating Reaffirmed at KeyCorp” was reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/davita-healthcare-partners-dva-hold-rating-reaffirmed-at-keycorp/1703043.html.
DaVita HealthCare Partners declared that its Board of Directors has approved a share repurchase plan on Tuesday, October 10th that permits the company to repurchase $1.50 billion in shares. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.
Institutional investors and hedge funds have recently made changes to their positions in the company. Pzena Investment Management LLC boosted its holdings in shares of DaVita HealthCare Partners by 2.1% during the 2nd quarter. Pzena Investment Management LLC now owns 3,398 shares of the company’s stock worth $220,000 after buying an additional 71 shares during the period. Eqis Capital Management Inc. boosted its holdings in shares of DaVita HealthCare Partners by 2.2% during the 2nd quarter. Eqis Capital Management Inc. now owns 4,600 shares of the company’s stock worth $298,000 after buying an additional 100 shares during the period. Thrivent Financial For Lutherans raised its stake in DaVita HealthCare Partners by 4.4% in the 1st quarter. Thrivent Financial For Lutherans now owns 5,730 shares of the company’s stock worth $389,000 after purchasing an additional 240 shares in the last quarter. Founders Capital Management LLC raised its stake in DaVita HealthCare Partners by 0.6% in the 2nd quarter. Founders Capital Management LLC now owns 93,824 shares of the company’s stock worth $6,076,000 after purchasing an additional 520 shares in the last quarter. Finally, Speece Thorson Capital Group Inc. raised its stake in DaVita HealthCare Partners by 0.5% in the 2nd quarter. Speece Thorson Capital Group Inc. now owns 280,515 shares of the company’s stock worth $18,166,000 after purchasing an additional 1,360 shares in the last quarter. 84.73% of the stock is owned by institutional investors.
About DaVita HealthCare Partners
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.